https://digital.library.adelaide.edu.au/dspace/bitstream/2440/104804/2/hdl_104804.pdf

Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

Dementia prevention, intervention, and care

The Lancet Commission on global mental health and sustainable development.

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)61462-8.pdf

Health, functioning, and disability in older adults—present status and future implications

BackgroundA trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). MethodsThis randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. ResultsIn ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (69...

/pdf/efficacy-of-the-herpes-zoster-subunit-vaccine-in-adults-70-38etw1j84r.pdf

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

http://repositorio.inger.gob.mx/jspui/bitstream/20.500.12100/17171/1/PIIS0140673614613477.pdf

Fan Wu

Papers

The burden of disease in older people and implications for health policy and practice